Skip to Content

Totect Approval History

FDA Approved: Yes (First approved September 6, 2007)
Brand name: Totect
Generic name: dexrazoxane
Company: TopoTarget A/S
Treatment for: Anthracycline Extravasation

Totect (dexrazoxane) is a topoisomerase inhibitor used as a detoxifying agent for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.

Development History and FDA Approval Process for Totect

DateArticle
Sep  7, 2007Approval Totect Approved in the United States
May 31, 2007TopoTarget elaborates on the specific initiatives to obtain FDA approval of Totect

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide